# Epify

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epify

- Industry: Biotechnology
- Headquarters: Maastricht, Netherlands
- Website: www.epify.nl/
- Total disclosed funding: $0.6M
- Latest round: Seed (Sep 25, 2019)
- Investors on record: 2

## About

Based in Limburg, Netherlands, and founded in 2019, Epify BV is a company that focuses on facilitating cancer diagnosis and personalized treatments through epigenetic biomarkers. The company was founded by Manon van Engeland and Wim van Criekinge. In September 2019, Epify BV raised EUR 0.5 million in seed funding from investors Brightlands Venture Partners and Novalis Biotech. 

The company specializes in the development of epigenetic biomarkers that regulate gene activity and are associated with various types of cancer. These biomarkers have been the focus of efforts to enable less invasive cancer detection and early intervention. Epify's goal is to leverage these biomarkers for earlier and more precise detection, enabling personalized oncology and offering improved prospects for cancer patients.

## Funding rounds

- Seed, Sep 25, 2019, $0.6M — Brightlands Venture Partners, Novalis Biotech

## Investors

- Brightlands Venture Partners (https://capitalatlas.ai/funds/brightlands-venture-partners) — Seed
- Novalis Biotech (https://capitalatlas.ai/funds/novalis-biotech) — Seed